Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients

被引：7
作者：
de Ciantis, M. [1 ,5 ]
Faure, C. [2 ]
Heudel, P-E [3 ]
Tredan, O. [3 ]
Rousset-Jablonski, C. [2 ,4 ]
机构：
[1] Univ Claude Bernard, Domaine Rockefeller, 8 Ave Rockefeller, F-69373 Lyon 8, France
[2] Ctr Leon Berard, Dept Chirurg, 28 Rue Laennec, F-69008 Lyon, France
[3] Ctr Leon Berard, Dept Cancerol Med, 28 Rue Laennec, F-69008 Lyon, France
[4] Ctr Hosp Lyon Sud, Serv Gynecol, 165 Chemin Grand Revoyet, F-69130 Pierre Benite, France
[5] Hosp Civils Lyon, Hop Femme Mere Enfant, Grp Hosp Est, Serv Gynecol & Obstet,Serv Med Reprod, 59 Blvd Pinel, F-69677 Bron, France
来源：
JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION | 2018年 / 47卷 / 06期
关键词：
Endocrine therapy; Ovarian suppression; GnRH agonist; Breast cancer; Estradiol; Premenopausal; SERUM TESTOSTERONE; THERAPY;
D O I：
10.1016/j.jogoh.2018.03.002
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
In premenopausal women treated for breast cancer, endocrine therapy combining an aromatase inhibitor (AI) and a gonadotropin-releasing hormone (GnRH) agonist (GA) for ovarian suppression may be indicated in high-risk or in metastatic cancer. AIs are effective in premenopausal women only when ovarian estrogen production is suppressed, a state achievable through the use of GAs. However, a complete suppression sometimes proves elusive. We report here three cases of ovarian suppression failure in premenopausal breast cancer patients who received adjuvant AI + GA. Frequency of GA administration, BMI, and young age could affect gonadotropin suppression and may be implied in these failures. Clinical monitoring of these patients is advisable, and hormone assays and pelvic ultrasound should be performed in case of symptoms of estrogen activity. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：261 / 264
页数：4
相关论文
共 12 条
  • [1] Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
    Bellet, Meritxell
    Gray, Kathryn P.
    Francis, Prudence A.
    Lang, Istvan
    Ciruelos, Eva
    Lluch, Ana
    Angel Climent, Miguel
    Catalan, Gustavo
    Avella, Antoni
    Bohn, Uriel
    Gonzalez-Martin, Antonio
    Ferrer, Roser
    Catalan, Roberto
    Azaro, Analia
    Rajasekaran, Agnita
    Morales, Josefa
    Vazquez, Josep
    Fleming, Gini F.
    Price, Karen N.
    Regan, Meredith M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1584 - U89
  • [2] Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
    Coates, A. S.
    Winer, E. P.
    Goldhirsch, A.
    Gelber, R. D.
    Gnant, M.
    Piccart-Gebhart, M.
    Thuerlimann, B.
    Senn, H. -J.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (08) : 1533 - 1546
  • [3] Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms?
    Daskivich, Timothy J.
    Oh, William K.
    [J]. UROLOGY, 2006, 67 (05) : 1084.e15 - 1084.e17
  • [4] Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in women
    Filicori, M
    Cognigni, GE
    Arnone, R
    Pocognoli, P
    Tabarelli, C
    Ciampaglia, W
    Taraborelli, S
    Casadio, P
    [J]. FERTILITY AND STERILITY, 1998, 69 (03) : 443 - 449
  • [5] Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
    Francis, Prudence A.
    Regan, Meredith M.
    Fleming, Gini F.
    Lang, Istvan
    Ciruelos, Eva
    Bellet, Meritxell
    Bonnefoi, Herve R.
    Climent, Miguel A.
    Da Prada, Gian Antonio
    Burstein, Harold J.
    Martino, Silvana
    Davidson, Nancy E.
    Geyer, Charles E., Jr.
    Walley, Barbara A.
    Coleman, Robert
    Kerbrat, Pierre
    Buchholz, Stefan
    Ingle, James N.
    Winer, Eric P.
    Rabaglio-Poretti, Manuela
    Maibach, Rudolf
    Ruepp, Barbara
    Giobbie-Hurder, Anita
    Price, Karen N.
    Colleoni, Marco
    Viale, Giuseppe
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (05) : 436 - 446
  • [6] JENKINS JM, 1994, CLIN ENDOCRINOL, V40, P357
  • [7] Efficacy and Safety of Leuprolide Acetate 3-Month Depot 11.25 Milligrams or 30 Milligrams for the Treatment of Central Precocious Puberty
    Lee, Peter A.
    Klein, Karen
    Mauras, Nelly
    Neely, E. Kirk
    Bloch, Clifford A.
    Larsen, Lois
    Mattia-Goldberg, Cynthia
    Chwalisz, Kristof
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (05) : 1572 - 1580
  • [8] Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer
    Morote, Juan
    Esquena, Salvador
    Abascal, Jose M.
    Trilla, Enrique
    Cecchini, Luis
    Raventos, Carles X.
    Catalan, Roberto
    Reventos, Jaurne
    [J]. UROLOGIA INTERNATIONALIS, 2006, 77 (02) : 135 - 138
  • [9] Reciprocal cross talk between gonadotropin-releasing hormone (GnRH) and prostaglandin receptors regulates GnRH receptor expression and differential gonadotropin secretion
    Naor, Zvi
    Jabbour, Henry N.
    Naidich, Michal
    Pawson, Adam J.
    Morgan, Kevin
    Battersby, Sharon
    Millar, Michael R.
    Brown, Pamela
    Millar, Robert P.
    [J]. MOLECULAR ENDOCRINOLOGY, 2007, 21 (02) : 524 - 537
  • [10] Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm
    Oefelein, MG
    Cornum, R
    [J]. JOURNAL OF UROLOGY, 2000, 164 (03) : 726 - 729
12